Reporting from ASCO 2022 Annual Meeting in Chicago, Chiara Cremolini puts into context presented research on panitumumab first-line therapy in RAS wild-type metastatic Colorectal Cancer. She details the results from the PARADIGM trial testing chemotherapy plus panitumumab vs chemotherapy plus bevacizumab, evidence from the TRIPLETE trial on the benefit of chemotherapy intensification with panitumumab, and findings from the IMPROVE study testing intermittent vs continuous panitumumab plus chemotherapy in this setting.
This video was supported with an unrestricted grant from Novartis.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.